Related Experiment Video
Updated: Aug 8, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Safety and efficacy with drug-eluting stent in ST-segment elevation and non-ST-segment elevation myocardial
Chang-Bum Park1, Cheol Whan Lee, Bong-Ki Lee
1Department of Medicine, Asan Medical Center, University of Ulsan, Seoul, Korea.
Insights
Drug-eluting stents (DES) show improved long-term safety and efficacy over bare metal stents (BMS) in acute myocardial infarction (AMI) patients. DES significantly reduced major adverse cardiovascular events at one year, primarily due to lower revascularization rates.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiovascular Research
Background:
- Drug-eluting stents (DES) are known to reduce repeat revascularization compared to bare metal stents (BMS).
- Limited data exists on the long-term safety and efficacy of DES specifically in patients experiencing acute myocardial infarction (AMI).
Purpose of the Study:
- To assess the safety and effectiveness of DES compared to BMS in patients diagnosed with AMI.
- Evaluate the incidence of major adverse cardiovascular events (MACE) within 30 days and one year post-intervention.
Main Methods:
- A comparative study involving 211 AMI patients treated with DES and 228 AMI patients treated with BMS.
- All interventions were performed within 7 days of symptom onset.
- Major adverse cardiovascular events (MACE), including death, reinfarction, and target vessel revascularization, were tracked at 30 days and 1 year.
Main Results:
- No significant difference in MACE or stent thrombosis rates was observed between DES and BMS groups at 30 days.
- At one year, DES demonstrated a significantly lower MACE rate (6.6% vs. 14.0%) compared to BMS.
- The reduction in MACE with DES was primarily driven by a lower rate of target vessel revascularization (4.8% vs. 9.6%).
Conclusions:
- DES are superior to BMS in mitigating the risk of major adverse cardiovascular events in patients with acute myocardial infarction.
- The findings support the use of DES for improved long-term outcomes in AMI patients.
Background:
Drug-eluting stents (DES) have been shown to reduce the need for repeat revascularization compared with bare metal stents (BMS). However, there is little information regarding the safety and long-term efficacy of DES in patients with acute myocardial infarction (AMI).
Hypothesis:
The aim of this study was to evaluate the safety and efficacy of DES in patients with AMI.
Methods:
Data from 211 consecutive patients with AMI treated with DES were compared with those from 228 consecutive patients with AMI treated with BMS. All patients were treated within 7 days of symptom onset. The incidence of major adverse cardiovascular events ([MACE]: death, reinfarction, and target vessel revascularization) was evaluated at 30 days and 1 year.
Results:
Baseline clinical and angiographic characteristics were similar for both stent groups. However, patients who received DES had longer lesion lengths (23.0 +/- 12.7 vs. 18.8 +/- 10.6 mm, respectively; p < 0.001) and smaller reference diameters (2.97 +/- 0.52 vs. 3.19 +/- 0.63 mm, respectively, p < 0.001). At 30 days, the incidence rates of MACE (DES vs. BMS: 2.2 vs. 1.9%, p = 1.000) and stent thrombosis (BMS vs. DES: 0.9 vs. 1.7%; p = 0.434) did not differ significantly between the groups. At 1 year, patients with DES had a lower rate of MACE (BMS vs. DES: 14.0 vs. 6.6%; p = 0.011) primarily due to a lower target vessel revascularization rate (BMS vs. DES: 9.6 vs. 4.8%; p = 0.028).
Conclusions:
The DES appear to be superior to the BMS in reducing the risk of MACE in patients with AMI.
